Merck Kgaa Unsp ADR (MKGAY) 34.8200 $MKGAY
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics Pipeline Review, H1 2015 - 23 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkcn8q/adenocarcinoma_of) has announced the addition of the "Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Amgen Inc. - Apceth GmbH & Co. KG - ArQule, Inc. - AstraZeneca PLC - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cerulean Pharma, Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Ganymed Pharmaceuticals AG - Genentech, Inc. - Gilead Sciences, Inc. - Mebiopharm Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Panacea Biotec Limited - Sanofi Drug Profiles - Agenmestencel-T - alpelisib - AMG-337 - avelumab - AZD-4547 - BI-853520 - BMS-833923 - cabazitaxel - catumaxomab - CRLX-101 - durvalumab tremelimumab - emibetuzumab - erismodegib - GS-5745 - IMAB-362 - indusatumab vedotin - ipatasertib - masitinib - MBP-426 - napabucasin - panitumumab - pembrolizumab - ramucirumab - solitomab - tivantinib - trastuzumab biosimilar - trastuzumab emtansine For more information visit http://www.researchandmarkets.com/research/nk...rcinoma_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CERU: 4.52 (+0.12), ARQL: 1.55 (+0.01), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Global Market Study on Cell and Tissue Culture Supplies 2014-2020: Thermo Fisher Scientific Dominates the $28 Billion Industry
M2 - Wed Jul 08, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k4vd8c/global_market) has announced the addition of the "Global Market Study on Cell and Tissue Culture Supplies: Asia to Witness Highest Growth by 2020" report to their offering. The global cell and tissue culture supplies market is estimated at USD 16,322.7 million in 2014. It is likely to grow with a CAGR of 9.5% and reach USD 28,108.3 million in 2020. Cell culture is the process by which cells are grown under appropriate conditions. Cell tissue culture requires a suitable cell or tissue which is grown in a suitable medium under aseptic conditions along with various regulators to maintain the growth of cells. Globally, the cell and tissue culture supplies market is witnessing significant growth due to increasing R&D in the field of cell and tissue engineering, rising applications of cell and tissue cultures and increasing prevalence of chronic diseases. North America has the largest market for the global cell and tissue culture supplies market. Instruments are the largest segment in the overall cell and tissue culture supplies market. In consumables market, reagents are the largest segment. In terms of growth, Asia is the fastest growing region, serum-free media is the fastest growing type of media and growth factors and cytokines are the fastest growing type of reagents. North America market for cell and tissue culture supplies is estimated at USD 8,079.0 million in 2014 and is expected to reach USD 14,079.0 million in 2020, growing at a CAGR of 9.7%. Some of the latest trends that have been observed in the global cell and tissue culture supplies market are the growing popularity contract research and serum-free, specialty, and customized media solutions. Thermo Fisher Scientific, Inc. is a leading player in the global cell and tissue culture supplies market, with a share of about 28% in 2013. Some of the other major players in cell and tissue culture supplies market are BD Diagnostics, EMD Millipore, Corning, Inc., Lonza Group and others. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Consumable Products Chapter 7 Market Size and Forecast by Instruments Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - Affymetrix, Inc. - Becton, Dickinson and Company - Corning, Inc. - Eppendorf AG - GE Healthcare - Lonza Group - Merck KGaA - Thermo Fisher Scientific, Inc. - VWR International, LLC - WHEATON Industries, Inc. For more information visit http://www.researchandmarkets.com/research/k4...bal_market
AFFX: 11.05 (+0.26)
Global OLED Material Market 2015-2019 - Market to grow at a CAGR of 21.5%
M2 - Tue Jul 07, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87k7vj/global_oled) has announced the addition of the "Global OLED Material Market 2015-2019" report to their offering. The analysts forecast the Global OLED Material market to grow at a CAGR of 21.5 percent over the period 2014-2019. The huge potential of the global OLED material market has led leading vendors such as LG and Samsung to increase their investments in R&D. With the rise in R&D spending, vendors are able to develop a set of technology standards for every end-product. The increase in R&D spending has also led to the development of advanced versions of OLED displays to be used for new applications. According to the report, OLED technology offers many advantages over the traditional display and lighting technologies. In addition, the use of organic materials in OLEDs enables energy management by consuming less power. OLED technology also enables end-users to develop compact devices that are thin, flexible, and have transparent panels. OLED display panels have an angle view of 180 degrees, making them an ideal choice for various display devices. Further, the report states that the limited life span of OLED materials is a challenge that hinders the market growth. This report covers the present scenario and the growth prospects of the Global OLED Material market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of OLED materials used for OLED displays and OLED lighting. The OLED materials considered for the market size are: - Anode - EML - Encapsulation - ETL - HIL - HTL/BTL/HBL - Substrate Key Vendors - DuPont - Merck KGaA - Samsung SDI Chemicals and Electronic Materials - Sumitomo Chemical - UDC - Universal Display Other Prominent Vendors - Doosan Corporation Electro-Materials - DOW - Duksan Hi-Metal - Hodogaya Chemical - Idemitsu Kosan - Konica Minolta - LG Chem For more information visit http://www.researchandmarkets.com/research/87...lobal_oled
The Weekender
Aviate - at Seeking Alpha - Sun Jul 05, 3:57AM CDT
Greece and Europe It is not over-exaggerating to say that all eyes are on Greece this weekend as the Greek people vote in the referendum. Where it was once seen as the most unlikely of outcomes, there now seems to be a real risk of Grexit,...
GREK: 11.26 (+0.95), TI: 13.19 (+0.48), RYAAY: 73.25 (+1.50), APOL: 14.01 (+0.43), BUD: 126.61 (+6.21), EU: 20.54 (-0.08), VOD: 36.46 (+1.07), PSO: 19.11 (+0.56)
Chromatography Resins Market in Drug Discovery - Global Market Trends & Forecasts to 2020: Increasing Demand for Therapeutic Antibodies
M2 - Thu Jul 02, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zfpzhx/chromatography) has announced the addition of the "Chromatography Resins Market in Drug Discovery by Technique (Ion Exchange, Affinity (Protein A, G & L), Hydrophobic Interaction, Size Exclusion, Multi Modal and Others) & Geography - Global Market Trends & Forecasts to 2020" report to their offering. The market for chromatography resins in drug discovery application is estimated at $238.07 Million in 2014 and is projected to grow at a CAGR of 7.0% between 2015 and 2020 The chromatography resins for drug discovery can be made of natural polymers, synthetic polymers or inorganic materials with ligands attached to them. This report on chromatography resins market in drug discovery covers all major regions such as Asia-Pacific, North America, Europe, and Rest of the World. The report analyzes market trends and forecasts from 2013 to 2020. Market estimations have been provided in terms of consumption volume (liters) and market revenue (USD). The global as well as regional markets have been segmented by technique such as ion exchange, affinity, hydrophobic interaction, size exclusion, multi-modal and others. The report analyzes the market dynamics such as drivers, restraints, and opportunities, and winning imperatives. Major companies such as General Electric Company, Bio-Rad Laboratories, Thermo Fisher, Tosoh Corporation, and Pall Corporation have been profiled in this report. The report also provide the analysis of competitive landscape based on the recent developments in the market. The chromatography resins market in drug discovery is highly consolidatesd with presence of a few global manufacturers who capture a large share of the market. These manufacturers are focused on providing advanced products to their customers and in the recent past have launched a number of new products. Chromatography resins for drug discovery can be classified into six categories based on the technique they are used in. Affinity chromatography is the largest segment, in terms of value. It accounts for around half the total market size, primarily due to its high cost. The Proetin A chromatography is the largest sub-type. The increase in critical diseases has led to high demand for therapeutic monoclonal antibodies, driving along with it the demand for Protein A affinity chromatography. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Chromatography Resins Market in Drug Discovery, By Technique 8 Chromatography Resins Market in Drug Discovery, Regional Analysis 9 Competitive Landscape 10 Company Profiles - Bio-Rad Laboratories, Inc. - General Electric Company - Genscript USA Inc. - Kaneka Corporation - Knauer Wissenschaftliche Ger?te GMBH - Merck KGAA - Pall Corporation - Purolite Corporation - Sepragen Corporation - Thermo Fisher Scientific Inc. - Tosoh Corporation For more information visit http://www.researchandmarkets.com/research/zf...matography
GE: 26.27 (+0.25), PLL: 125.45 (+0.04)
EMD Serono Announces EUR 1.2 million Grant for Fertility Innovation (GFI) for 2015 / 16
PR Newswire - Wed Jun 17, 7:00AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced its strong support of the Grant for Fertility Innovation (GFI) fund with grants totaling up to EUR 1.2 million for the years 2015 / 2016. The announcement was made during the 31st annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) currently taking place in Lisbon.
Will Merck (MKGAY) Stock be Helped by EC Approval of $17 Billion Sigma-Aldrich Deal?
at The Street - Mon Jun 15, 1:58PM CDT
Merck (MKGAY) shares are falling but could rebound after European officials approved its $17 billion acquisition of Sigma-Aldrich.
Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives Approval from European Union Regulators and from Chinese Ministry of Commerce
PR Newswire - Mon Jun 15, 1:33PM CDT
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the European Commission (the "EC"
has conditionally cleared the planned acquisition of the Company by Merck KGaA, Darmstadt, Germany (the "Transaction" . Sigma-Aldrich also announced it has obtained full clearance of the Transaction from the Chinese Ministry of Commerce.
SIAL: 139.36 (+0.04)
EMD Millipore Introduces the Mobius® 2000 Liter Single-Use Bioreactor with Industry-leading Design for Ease-of-Use
PR Newswire - Mon Jun 15, 7:00AM CDT
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced the Mobius® 2000 liter single-use bioreactor. The 2000 liter bioreactor joins the Mobius® stirred tank bioreactor portfolio (from 3 to 2000 liters) that provides the ultimate in flexibility, scalability, and convenience. With configurable software, hardware, and single-use Flexware® assemblies for suspension and adherent cell culture applications, the new 2000 liter single-use bioreactor incorporates industry-leading design features that enable users to easily optimize their upstream process.
EMD Millipore Expands Provantage® Biodevelopment Services with Addition of Provantage® Clone Generation Service
PR Newswire - Mon Jun 15, 7:00AM CDT
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today announced expansion of its Provantage® Biodevelopment Services to include a Clone Generation Service. With this addition, the Company now provides a full range of services for optimizing yield, productivity, consistency and efficiency of clinical scale drug products.
Merck KGaA, Darmstadt, Germany: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark
PR Newswire - Sun Jun 14, 2:15AM CDT
Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced that the two innovative fertility technologies Gavi and Geri have cleared a major milestone, achieving CE Mark certification. Merck KGaA, Darmstadt, Germany, recently signed a global collaboration agreement with Genea Biomedx, the manufacturer of both products. With this partnership, Merck KGaA, Darmstadt, Germany, received global marketing and commercialization rights to Genea Biomedx's product portfolio. All products will be provided through Merck KGaA, Darmstadt, Germany's Fertility Technologies unit.
Corporate Reputation of Pharma in 2014 - a Perspective of Patient Groups with an Interest in Neurological Conditions - 2015 Edition
M2 - Fri Jun 12, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9rstp6/corporate) has announced the addition of the "Corporate Reputation of Pharma in 2014 - a Perspective of Patient Groups with an Interest in Neurological Conditions - 2nd Edition " report to their offering. This independent study, funded by the author, represents the perspectives from 165 patient groups with an interest in neurological conditions on the corporate reputation of 18 individual pharma companies (and of the pharma industry as a whole) in 2014. This report compares the results from the neurological patient organisations with 1,150 patient groups from all therapy areas [which responded to the report: The Corporate Reputation of Pharma in 2014 - the Patient Perspective, published in February 2015] and with the responses of neurological-condition patient groups in the previous year's survey (2013). For 2014, Lundbeck emerges as most outstanding of the 18 pharma companies assessed for corporate reputation by patient groups with an interest in neurological conditions. The firm takes top spot for no fewer than five of the total six indicators used by the author to measure corporate reputation. About the corporate stars - Lundbeck is rated top-perfomer overall by the neurological patient groups and in first place for five of the six indicators of corporate reputation used by PatientView - namely, for its high-quality patient information and useful products, its records on patient safety and transparency with external stakeholders and for its integrity. The Danish headquartered company, which moves up to the top from sixth position in 2013, is the only firm out of the 18 reviewed to concentrate solely on the development of mental health and neuroscience products, a focus which it has maintained for over 50 years. The increase is also due to the fact that the company rankings had slid previously after the imposition by a European Commission fine in June 2013. - Teva is in second place overall, winning its best rankings (second) for its records on patient safety and transparency. Based in Israel, the world's leading generics manufacturer was not included in the 2013 study, but this year the neurology patient groups applaud it for its continuing development of the multiple sclerosis (MS) drug treatment Copaxone (glatiramer acetate), and its Shared Solutions programme of support for patients receiving the drug, plus its wide range of generic drugs in the neurological therapy area and ongoing R&D in other neurological conditions such as migraine. - Biogen Idec, in third place overall, wins its highest individual corporate score for integrity, where it is placed second. The US-based biotechnology company, which was not included in the 2013 report, is highly praised by the neurology patient groups for its robust product portfolio and R&D pipeline in this therapy area. - UCB, also in third position overall this year, was not included in 2013's listings. The Brussels-headquartered company says it aspires to be the patient-centric global biopharma leader, and this year it ranks first in the author's survey of neurological patient groups for its patient-centred strategy. Central to this effort is the firm's groundbreaking Patient Engagement Framework which, the company says, informs its R&D process. - Sanofi is in fifth place overall. The French-based biopharma major has moved up from 12 in 2013, largely as a result of the neurology patient groups' increased appreciation of its R&D pipelines, particularly in MS. Descending stars - The 2014 survey of neurological patient groups reveals that last year's five top-ranking firms have all experienced significant falls in terms of corporate reputation. Eli Lilly, which led the table in 2013, has now fallen to eighth place, while Pfizer drops from second spot to 10th, GlaxoSmithKline from third to ninth, AstraZeneca from fourth to 16 and Novartis from fifth to seventh place. The reasons for these significant movements up and down the corporate reputation tables are very largely to do with neurological patient groups' conviction that the two most important factors in determining a pharma company's reputation are the quality of its drug portfolio and whether or not it has adopted a fair pricing policy, comments the author. Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 18 Companies - Profiles of 18 Companies - Profile of Respondents Companies Mentioned - AbbVie - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Eli Lilly (Lilly) - GlaxoSmithKline (GSK) - Janssen - Lundbeck - Merck & Co (USA) - Merck KGaA (Germany) - Novartis - Pfizer - Roche - Sanofi - Teva - UCB For more information visit http://www.researchandmarkets.com/research/9rstp6/corporate
BIIB: 388.23 (-11.06), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20)
Corporate Reputation of Pharma in 2014 - A Perspective of Cancer Patient Groups
M2 - Fri Jun 12, 9:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4wl9nv/corporate) has announced the addition of the "Corporate Reputation of Pharma in 2014 - a Perspective of Cancer Patient Groups - 2nd Edition" report to their offering. This independent study, funded by the author, represents the perspectives from 197 groups representing cancer patients on the corporate reputation of 21 individual pharma companies and of the pharma industry as a whole in 2014. The results from the respondent cancer patient groups are compared in this report with those from the entire body of 1,150 respondent patient groups (the latter cover all therapy areas), and with the responses of cancer patient groups in the previous year's survey (2013). About the corporate stars - Novartis now has the best corporate reputation out of all 21 pharma companies surveyed, say the cancer patient groups. The Swiss-based major has moved to the top spot from second place overall in 2013 and holds the lead ranking for no fewer than five of the report's total six indicators - being ranked best for having the most effective patient-centred strategy, the best patient information, patient safety record, integrity and transparency. - Roche slips to second place overall from the top spot last year, but the cancer patient groups rank the Swiss biopharma in first place for its provision of useful high-quality products. - Pfizer moves up to third place overall, from seventh in 2013. The US biopharma's highest ranking by indicator puts it third for providing patients with useful, high-quality products. - Astellas is in fourth position. The Japanese company was not assessed by the cancer patient groups in 2013. - Janssen is in fifth place overall, the same position as it held in 2013, and for 2014 the US-headquartered firm is placed second for integrity. What matters to cancer patient groups - Cancer patient groups believe that the most important influences on a pharma company's corporate reputation are whether it has a patient-centred strategy and that it operates fair pricing policies; around 20% of the groups said that both these factors are of prime importance. Indeed, the steep declines in corporate reputation experienced by several leading firms in 2014's survey appear to be linked to perceptions of poor communication about controversial clinical trial data, the setting of very high prices which potentially limit patient access to valuable new drugs, and reported involvement in pay-for-delay deals, which seek to delay the market entry of competitive new generics. - Other important influences on a company's reputation are that it provides high-quality, useful products and ensures patient safety; these are cited as top priority by 15% and 13% of the cancer patient groups, respectively. Conversely, being innovative was most important for only 5%, and providing access to clinical trials for just 4%. - Nevertheless, the PatientView survey also finds that efforts by companies to significantly increase their R&D investments in cancer treatment, such as Pfizer, and personalised medicine (Novartis/Roche), are winning appreciation from patient groups. Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 21 Companies - Profiles of 21 Companies - Profile of Respondents Companies Mentioned - AbbVie - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer-Ingelheim - Bristol-Myers Squibb - Celgene - Eli Lilly (Lilly) - Gilead Sciences - GlaxoSmithKline (GSK) - Janssen - Merck & Co (US) - Merck KGaA (Germany) - Novartis - Pfizer - Roche - Sanofi - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/4wl9nv/corporate
GILD: 113.74 (+0.38), BAX: 37.61 (+0.59), MRK: 57.95 (+0.57), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Thu Jun 11, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnvpb5/transitional_cell) has announced the addition of the "Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Astellas Pharma Inc. - AstraZeneca PLC - Boston Biomedical, Inc. - Corcept Therapeutics Incorporated - Eli Lilly and Company - Exelixis, Inc. - GlaxoSmithKline plc - Innate Therapeutics Limited - Merck & Co., Inc. - Merck KGaA - Mirati Therapeutics Inc. - Novartis AG - Pfizer Inc. - Sanofi - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited Drug Profiles - ACP-196 - AGS-15E - ALT-801 - amrubicin hydrochloride - ASG-15ME - avelumab - AZD-4547 - BBI-503 - buparlisib hydrochloride - cabazitaxel - cabozantinib s-malate - CEP-11981 - enfortumab vedotin - mifepristone - MIS-416 - mocetinostat - palbociclib - pembrolizumab - ramucirumab - SAR-408701 - SNX-5422 - trametinib dimethyl sulfoxide For more information visit http://www.researchandmarkets.com/research/jn...ional_cell
PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81), MRTX: 31.67 (+0.81), GSK: 42.45 (+0.65), CORT: 5.88 (+0.14), NVS: 103.22 (+3.20), EXEL: 3.68 (+0.25)
Gastroesophageal (GE) Junction Carcinomas Pipeline Review, H1 2015 - 14 Companies & 17 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/27fwrv/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Basilea Pharmaceutica AG - Bristol-Myers Squibb Company - Celltrion, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Merck & Co., Inc. - Merck KGaA - Merrimack Pharmaceuticals, Inc. - Ono Pharmaceutical Co., Ltd. - Taiho Pharmaceutical Co., Ltd. Drug Profiles - (tegafur gimeracil oteracil) - avelumab - BAL-101553 - cabozantinib s-malate - DKN-01 - gefitinib - GS-5745 - ipilimumab - MK-2206 - MM-111 - nimotuzumab - nivolumab - pertuzumab - SNX-5422 - trastuzumab biosimilar - trebananib - varlitinib For more information visit http://www.researchandmarkets.com/research/27...esophageal
MACK: 12.08 (+0.43), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), EXEL: 3.68 (+0.25)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 108.33 (+0.22), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), CALA: 6.77 (unch), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
Merck KGaA, Darmstadt, Germany, Illumina and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment
PR Newswire - Mon Jun 08, 7:06AM CDT
Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, Illumina Inc., San Diego, US, a leader in developing and commercializing systems for analysis of genetic variation and function, and Genea Limited, Sydney, Australia, which develops innovative fertility technologies.
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics Pipeline Review, H1 2015 - 23 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkcn8q/adenocarcinoma_of) has announced the addition of the "Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Amgen Inc. - Apceth GmbH & Co. KG - ArQule, Inc. - AstraZeneca PLC - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Cerulean Pharma, Inc. - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Ganymed Pharmaceuticals AG - Genentech, Inc. - Gilead Sciences, Inc. - Mebiopharm Co., Ltd. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Panacea Biotec Limited - Sanofi Drug Profiles - Agenmestencel-T - alpelisib - AMG-337 - avelumab - AZD-4547 - BI-853520 - BMS-833923 - cabazitaxel - catumaxomab - CRLX-101 - durvalumab tremelimumab - emibetuzumab - erismodegib - GS-5745 - IMAB-362 - indusatumab vedotin - ipatasertib - masitinib - MBP-426 - napabucasin - panitumumab - pembrolizumab - ramucirumab - solitomab - tivantinib - trastuzumab biosimilar - trastuzumab emtansine For more information visit http://www.researchandmarkets.com/research/nk...rcinoma_of About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CERU: 4.52 (+0.12), ARQL: 1.55 (+0.01), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Global Market Study on Cell and Tissue Culture Supplies 2014-2020: Thermo Fisher Scientific Dominates the $28 Billion Industry
M2 - Wed Jul 08, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k4vd8c/global_market) has announced the addition of the "Global Market Study on Cell and Tissue Culture Supplies: Asia to Witness Highest Growth by 2020" report to their offering. The global cell and tissue culture supplies market is estimated at USD 16,322.7 million in 2014. It is likely to grow with a CAGR of 9.5% and reach USD 28,108.3 million in 2020. Cell culture is the process by which cells are grown under appropriate conditions. Cell tissue culture requires a suitable cell or tissue which is grown in a suitable medium under aseptic conditions along with various regulators to maintain the growth of cells. Globally, the cell and tissue culture supplies market is witnessing significant growth due to increasing R&D in the field of cell and tissue engineering, rising applications of cell and tissue cultures and increasing prevalence of chronic diseases. North America has the largest market for the global cell and tissue culture supplies market. Instruments are the largest segment in the overall cell and tissue culture supplies market. In consumables market, reagents are the largest segment. In terms of growth, Asia is the fastest growing region, serum-free media is the fastest growing type of media and growth factors and cytokines are the fastest growing type of reagents. North America market for cell and tissue culture supplies is estimated at USD 8,079.0 million in 2014 and is expected to reach USD 14,079.0 million in 2020, growing at a CAGR of 9.7%. Some of the latest trends that have been observed in the global cell and tissue culture supplies market are the growing popularity contract research and serum-free, specialty, and customized media solutions. Thermo Fisher Scientific, Inc. is a leading player in the global cell and tissue culture supplies market, with a share of about 28% in 2013. Some of the other major players in cell and tissue culture supplies market are BD Diagnostics, EMD Millipore, Corning, Inc., Lonza Group and others. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry Overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Consumable Products Chapter 7 Market Size and Forecast by Instruments Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - Affymetrix, Inc. - Becton, Dickinson and Company - Corning, Inc. - Eppendorf AG - GE Healthcare - Lonza Group - Merck KGaA - Thermo Fisher Scientific, Inc. - VWR International, LLC - WHEATON Industries, Inc. For more information visit http://www.researchandmarkets.com/research/k4...bal_market
AFFX: 11.05 (+0.26)
Global OLED Material Market 2015-2019 - Market to grow at a CAGR of 21.5%
M2 - Tue Jul 07, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87k7vj/global_oled) has announced the addition of the "Global OLED Material Market 2015-2019" report to their offering. The analysts forecast the Global OLED Material market to grow at a CAGR of 21.5 percent over the period 2014-2019. The huge potential of the global OLED material market has led leading vendors such as LG and Samsung to increase their investments in R&D. With the rise in R&D spending, vendors are able to develop a set of technology standards for every end-product. The increase in R&D spending has also led to the development of advanced versions of OLED displays to be used for new applications. According to the report, OLED technology offers many advantages over the traditional display and lighting technologies. In addition, the use of organic materials in OLEDs enables energy management by consuming less power. OLED technology also enables end-users to develop compact devices that are thin, flexible, and have transparent panels. OLED display panels have an angle view of 180 degrees, making them an ideal choice for various display devices. Further, the report states that the limited life span of OLED materials is a challenge that hinders the market growth. This report covers the present scenario and the growth prospects of the Global OLED Material market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of OLED materials used for OLED displays and OLED lighting. The OLED materials considered for the market size are: - Anode - EML - Encapsulation - ETL - HIL - HTL/BTL/HBL - Substrate Key Vendors - DuPont - Merck KGaA - Samsung SDI Chemicals and Electronic Materials - Sumitomo Chemical - UDC - Universal Display Other Prominent Vendors - Doosan Corporation Electro-Materials - DOW - Duksan Hi-Metal - Hodogaya Chemical - Idemitsu Kosan - Konica Minolta - LG Chem For more information visit http://www.researchandmarkets.com/research/87...lobal_oled
The Weekender
Aviate - at Seeking Alpha - Sun Jul 05, 3:57AM CDT
Greece and Europe It is not over-exaggerating to say that all eyes are on Greece this weekend as the Greek people vote in the referendum. Where it was once seen as the most unlikely of outcomes, there now seems to be a real risk of Grexit,...
GREK: 11.26 (+0.95), TI: 13.19 (+0.48), RYAAY: 73.25 (+1.50), APOL: 14.01 (+0.43), BUD: 126.61 (+6.21), EU: 20.54 (-0.08), VOD: 36.46 (+1.07), PSO: 19.11 (+0.56)
Chromatography Resins Market in Drug Discovery - Global Market Trends & Forecasts to 2020: Increasing Demand for Therapeutic Antibodies
M2 - Thu Jul 02, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zfpzhx/chromatography) has announced the addition of the "Chromatography Resins Market in Drug Discovery by Technique (Ion Exchange, Affinity (Protein A, G & L), Hydrophobic Interaction, Size Exclusion, Multi Modal and Others) & Geography - Global Market Trends & Forecasts to 2020" report to their offering. The market for chromatography resins in drug discovery application is estimated at $238.07 Million in 2014 and is projected to grow at a CAGR of 7.0% between 2015 and 2020 The chromatography resins for drug discovery can be made of natural polymers, synthetic polymers or inorganic materials with ligands attached to them. This report on chromatography resins market in drug discovery covers all major regions such as Asia-Pacific, North America, Europe, and Rest of the World. The report analyzes market trends and forecasts from 2013 to 2020. Market estimations have been provided in terms of consumption volume (liters) and market revenue (USD). The global as well as regional markets have been segmented by technique such as ion exchange, affinity, hydrophobic interaction, size exclusion, multi-modal and others. The report analyzes the market dynamics such as drivers, restraints, and opportunities, and winning imperatives. Major companies such as General Electric Company, Bio-Rad Laboratories, Thermo Fisher, Tosoh Corporation, and Pall Corporation have been profiled in this report. The report also provide the analysis of competitive landscape based on the recent developments in the market. The chromatography resins market in drug discovery is highly consolidatesd with presence of a few global manufacturers who capture a large share of the market. These manufacturers are focused on providing advanced products to their customers and in the recent past have launched a number of new products. Chromatography resins for drug discovery can be classified into six categories based on the technique they are used in. Affinity chromatography is the largest segment, in terms of value. It accounts for around half the total market size, primarily due to its high cost. The Proetin A chromatography is the largest sub-type. The increase in critical diseases has led to high demand for therapeutic monoclonal antibodies, driving along with it the demand for Protein A affinity chromatography. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Chromatography Resins Market in Drug Discovery, By Technique 8 Chromatography Resins Market in Drug Discovery, Regional Analysis 9 Competitive Landscape 10 Company Profiles - Bio-Rad Laboratories, Inc. - General Electric Company - Genscript USA Inc. - Kaneka Corporation - Knauer Wissenschaftliche Ger?te GMBH - Merck KGAA - Pall Corporation - Purolite Corporation - Sepragen Corporation - Thermo Fisher Scientific Inc. - Tosoh Corporation For more information visit http://www.researchandmarkets.com/research/zf...matography
GE: 26.27 (+0.25), PLL: 125.45 (+0.04)
EMD Serono Announces EUR 1.2 million Grant for Fertility Innovation (GFI) for 2015 / 16
PR Newswire - Wed Jun 17, 7:00AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced its strong support of the Grant for Fertility Innovation (GFI) fund with grants totaling up to EUR 1.2 million for the years 2015 / 2016. The announcement was made during the 31st annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) currently taking place in Lisbon.
Will Merck (MKGAY) Stock be Helped by EC Approval of $17 Billion Sigma-Aldrich Deal?
at The Street - Mon Jun 15, 1:58PM CDT
Merck (MKGAY) shares are falling but could rebound after European officials approved its $17 billion acquisition of Sigma-Aldrich.
Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives Approval from European Union Regulators and from Chinese Ministry of Commerce
PR Newswire - Mon Jun 15, 1:33PM CDT
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the European Commission (the "EC"
has conditionally cleared the planned acquisition of the Company by Merck KGaA, Darmstadt, Germany (the "Transaction" . Sigma-Aldrich also announced it has obtained full clearance of the Transaction from the Chinese Ministry of Commerce. SIAL: 139.36 (+0.04)
EMD Millipore Introduces the Mobius® 2000 Liter Single-Use Bioreactor with Industry-leading Design for Ease-of-Use
PR Newswire - Mon Jun 15, 7:00AM CDT
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced the Mobius® 2000 liter single-use bioreactor. The 2000 liter bioreactor joins the Mobius® stirred tank bioreactor portfolio (from 3 to 2000 liters) that provides the ultimate in flexibility, scalability, and convenience. With configurable software, hardware, and single-use Flexware® assemblies for suspension and adherent cell culture applications, the new 2000 liter single-use bioreactor incorporates industry-leading design features that enable users to easily optimize their upstream process.
EMD Millipore Expands Provantage® Biodevelopment Services with Addition of Provantage® Clone Generation Service
PR Newswire - Mon Jun 15, 7:00AM CDT
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today announced expansion of its Provantage® Biodevelopment Services to include a Clone Generation Service. With this addition, the Company now provides a full range of services for optimizing yield, productivity, consistency and efficiency of clinical scale drug products.
Merck KGaA, Darmstadt, Germany: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark
PR Newswire - Sun Jun 14, 2:15AM CDT
Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced that the two innovative fertility technologies Gavi and Geri have cleared a major milestone, achieving CE Mark certification. Merck KGaA, Darmstadt, Germany, recently signed a global collaboration agreement with Genea Biomedx, the manufacturer of both products. With this partnership, Merck KGaA, Darmstadt, Germany, received global marketing and commercialization rights to Genea Biomedx's product portfolio. All products will be provided through Merck KGaA, Darmstadt, Germany's Fertility Technologies unit.
Corporate Reputation of Pharma in 2014 - a Perspective of Patient Groups with an Interest in Neurological Conditions - 2015 Edition
M2 - Fri Jun 12, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9rstp6/corporate) has announced the addition of the "Corporate Reputation of Pharma in 2014 - a Perspective of Patient Groups with an Interest in Neurological Conditions - 2nd Edition " report to their offering. This independent study, funded by the author, represents the perspectives from 165 patient groups with an interest in neurological conditions on the corporate reputation of 18 individual pharma companies (and of the pharma industry as a whole) in 2014. This report compares the results from the neurological patient organisations with 1,150 patient groups from all therapy areas [which responded to the report: The Corporate Reputation of Pharma in 2014 - the Patient Perspective, published in February 2015] and with the responses of neurological-condition patient groups in the previous year's survey (2013). For 2014, Lundbeck emerges as most outstanding of the 18 pharma companies assessed for corporate reputation by patient groups with an interest in neurological conditions. The firm takes top spot for no fewer than five of the total six indicators used by the author to measure corporate reputation. About the corporate stars - Lundbeck is rated top-perfomer overall by the neurological patient groups and in first place for five of the six indicators of corporate reputation used by PatientView - namely, for its high-quality patient information and useful products, its records on patient safety and transparency with external stakeholders and for its integrity. The Danish headquartered company, which moves up to the top from sixth position in 2013, is the only firm out of the 18 reviewed to concentrate solely on the development of mental health and neuroscience products, a focus which it has maintained for over 50 years. The increase is also due to the fact that the company rankings had slid previously after the imposition by a European Commission fine in June 2013. - Teva is in second place overall, winning its best rankings (second) for its records on patient safety and transparency. Based in Israel, the world's leading generics manufacturer was not included in the 2013 study, but this year the neurology patient groups applaud it for its continuing development of the multiple sclerosis (MS) drug treatment Copaxone (glatiramer acetate), and its Shared Solutions programme of support for patients receiving the drug, plus its wide range of generic drugs in the neurological therapy area and ongoing R&D in other neurological conditions such as migraine. - Biogen Idec, in third place overall, wins its highest individual corporate score for integrity, where it is placed second. The US-based biotechnology company, which was not included in the 2013 report, is highly praised by the neurology patient groups for its robust product portfolio and R&D pipeline in this therapy area. - UCB, also in third position overall this year, was not included in 2013's listings. The Brussels-headquartered company says it aspires to be the patient-centric global biopharma leader, and this year it ranks first in the author's survey of neurological patient groups for its patient-centred strategy. Central to this effort is the firm's groundbreaking Patient Engagement Framework which, the company says, informs its R&D process. - Sanofi is in fifth place overall. The French-based biopharma major has moved up from 12 in 2013, largely as a result of the neurology patient groups' increased appreciation of its R&D pipelines, particularly in MS. Descending stars - The 2014 survey of neurological patient groups reveals that last year's five top-ranking firms have all experienced significant falls in terms of corporate reputation. Eli Lilly, which led the table in 2013, has now fallen to eighth place, while Pfizer drops from second spot to 10th, GlaxoSmithKline from third to ninth, AstraZeneca from fourth to 16 and Novartis from fifth to seventh place. The reasons for these significant movements up and down the corporate reputation tables are very largely to do with neurological patient groups' conviction that the two most important factors in determining a pharma company's reputation are the quality of its drug portfolio and whether or not it has adopted a fair pricing policy, comments the author. Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 18 Companies - Profiles of 18 Companies - Profile of Respondents Companies Mentioned - AbbVie - AstraZeneca - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Eli Lilly (Lilly) - GlaxoSmithKline (GSK) - Janssen - Lundbeck - Merck & Co (USA) - Merck KGaA (Germany) - Novartis - Pfizer - Roche - Sanofi - Teva - UCB For more information visit http://www.researchandmarkets.com/research/9rstp6/corporate
BIIB: 388.23 (-11.06), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20)
Corporate Reputation of Pharma in 2014 - A Perspective of Cancer Patient Groups
M2 - Fri Jun 12, 9:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4wl9nv/corporate) has announced the addition of the "Corporate Reputation of Pharma in 2014 - a Perspective of Cancer Patient Groups - 2nd Edition" report to their offering. This independent study, funded by the author, represents the perspectives from 197 groups representing cancer patients on the corporate reputation of 21 individual pharma companies and of the pharma industry as a whole in 2014. The results from the respondent cancer patient groups are compared in this report with those from the entire body of 1,150 respondent patient groups (the latter cover all therapy areas), and with the responses of cancer patient groups in the previous year's survey (2013). About the corporate stars - Novartis now has the best corporate reputation out of all 21 pharma companies surveyed, say the cancer patient groups. The Swiss-based major has moved to the top spot from second place overall in 2013 and holds the lead ranking for no fewer than five of the report's total six indicators - being ranked best for having the most effective patient-centred strategy, the best patient information, patient safety record, integrity and transparency. - Roche slips to second place overall from the top spot last year, but the cancer patient groups rank the Swiss biopharma in first place for its provision of useful high-quality products. - Pfizer moves up to third place overall, from seventh in 2013. The US biopharma's highest ranking by indicator puts it third for providing patients with useful, high-quality products. - Astellas is in fourth position. The Japanese company was not assessed by the cancer patient groups in 2013. - Janssen is in fifth place overall, the same position as it held in 2013, and for 2014 the US-headquartered firm is placed second for integrity. What matters to cancer patient groups - Cancer patient groups believe that the most important influences on a pharma company's corporate reputation are whether it has a patient-centred strategy and that it operates fair pricing policies; around 20% of the groups said that both these factors are of prime importance. Indeed, the steep declines in corporate reputation experienced by several leading firms in 2014's survey appear to be linked to perceptions of poor communication about controversial clinical trial data, the setting of very high prices which potentially limit patient access to valuable new drugs, and reported involvement in pay-for-delay deals, which seek to delay the market entry of competitive new generics. - Other important influences on a company's reputation are that it provides high-quality, useful products and ensures patient safety; these are cited as top priority by 15% and 13% of the cancer patient groups, respectively. Conversely, being innovative was most important for only 5%, and providing access to clinical trials for just 4%. - Nevertheless, the PatientView survey also finds that efforts by companies to significantly increase their R&D investments in cancer treatment, such as Pfizer, and personalised medicine (Novartis/Roche), are winning appreciation from patient groups. Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 21 Companies - Profiles of 21 Companies - Profile of Respondents Companies Mentioned - AbbVie - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Boehringer-Ingelheim - Bristol-Myers Squibb - Celgene - Eli Lilly (Lilly) - Gilead Sciences - GlaxoSmithKline (GSK) - Janssen - Merck & Co (US) - Merck KGaA (Germany) - Novartis - Pfizer - Roche - Sanofi - Takeda - Teva For more information visit http://www.researchandmarkets.com/research/4wl9nv/corporate
GILD: 113.74 (+0.38), BAX: 37.61 (+0.59), MRK: 57.95 (+0.57), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Thu Jun 11, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnvpb5/transitional_cell) has announced the addition of the "Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Altor BioScience Corporation - Astellas Pharma Inc. - AstraZeneca PLC - Boston Biomedical, Inc. - Corcept Therapeutics Incorporated - Eli Lilly and Company - Exelixis, Inc. - GlaxoSmithKline plc - Innate Therapeutics Limited - Merck & Co., Inc. - Merck KGaA - Mirati Therapeutics Inc. - Novartis AG - Pfizer Inc. - Sanofi - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited Drug Profiles - ACP-196 - AGS-15E - ALT-801 - amrubicin hydrochloride - ASG-15ME - avelumab - AZD-4547 - BBI-503 - buparlisib hydrochloride - cabazitaxel - cabozantinib s-malate - CEP-11981 - enfortumab vedotin - mifepristone - MIS-416 - mocetinostat - palbociclib - pembrolizumab - ramucirumab - SAR-408701 - SNX-5422 - trametinib dimethyl sulfoxide For more information visit http://www.researchandmarkets.com/research/jn...ional_cell
PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81), MRTX: 31.67 (+0.81), GSK: 42.45 (+0.65), CORT: 5.88 (+0.14), NVS: 103.22 (+3.20), EXEL: 3.68 (+0.25)
Gastroesophageal (GE) Junction Carcinomas Pipeline Review, H1 2015 - 14 Companies & 17 Drug Profiles
M2 - Thu Jun 11, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/27fwrv/gastroesophageal) has announced the addition of the "Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca PLC - Basilea Pharmaceutica AG - Bristol-Myers Squibb Company - Celltrion, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Merck & Co., Inc. - Merck KGaA - Merrimack Pharmaceuticals, Inc. - Ono Pharmaceutical Co., Ltd. - Taiho Pharmaceutical Co., Ltd. Drug Profiles - (tegafur gimeracil oteracil) - avelumab - BAL-101553 - cabozantinib s-malate - DKN-01 - gefitinib - GS-5745 - ipilimumab - MK-2206 - MM-111 - nimotuzumab - nivolumab - pertuzumab - SNX-5422 - trastuzumab biosimilar - trebananib - varlitinib For more information visit http://www.researchandmarkets.com/research/27...esophageal
MACK: 12.08 (+0.43), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79), BMY: 69.27 (+1.38), EXEL: 3.68 (+0.25)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 108.33 (+0.22), IDRA: 3.49 (+0.05), GILD: 113.74 (+0.38), CALA: 6.77 (unch), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14), KPTI: 25.57 (+0.24)
Merck KGaA, Darmstadt, Germany, Illumina and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment
PR Newswire - Mon Jun 08, 7:06AM CDT
Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced the formation of the Global Fertility Alliance, a new collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. The alliance is a partnership between the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, Illumina Inc., San Diego, US, a leader in developing and commercializing systems for analysis of genetic variation and function, and Genea Limited, Sydney, Australia, which develops innovative fertility technologies.
